Alkermes, Inc. (NASDAQ:ALKS)

CAPS Rating: 4 out of 5

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.

Recs

0
Player Avatar geomedf (< 20) Submitted: 1/27/2012 3:47:37 PM : Outperform Start Price: $19.10 ALKS Score: -5.89

Succeeded in their third attempt to gain U.S. clearance for Bydureon, a once-weekly version of Amylin’s diabetes shot.

Featured Broker Partners


Advertisement